ImmuneOnco Receives NMPA Approval for Phase III Clinical Trial of CD47 Inhibitor TIMDARPACEPT
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...
Drug
Shanghai Henlius Biotech Advances TIGIT-Targeting HLX53 to Phase II Clinical Trial for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc., (HKG: 2696), a biopharmaceutical company based in China, has received approval...
Amgen’s Tezspire Shows Promise in Phase IIa COPD Trial, Reduces Exacerbations
Amgen (NASDAQ: AMGN), a multinational biopharmaceutical company, has this week announced results from a Phase...
Sichuan Biokin’s BL-B01D1 Earns Breakthrough Designation for Nasopharyngeal Carcinoma Treatment
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a biopharmaceutical company based in China, has announced...
Innovent Biologics’ IBI133 Receives Tacit Approval for Clinical Trial from China’s CDE
The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approval to...
Shionogi’s Xofluza Gains Approval in Taiwan for Pediatric Influenza Treatment and Prophylaxis
Shionogi & Co., Ltd, a leading Japanese pharmaceutical company, has announced that it has received...
Kangtai Biological Receives NMPA Approval for 20-Valent Pneumococcal Vaccine Clinical Trial
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading biopharmaceutical company in China, has...
KPC Pharmaceuticals Gets NMPA Green Light for Clinical Trial on Familial Mediterranean Fever Treatment
Yunnan-based KPC Pharmaceuticals Inc., (SHA: 600422) has announced that it has received clinical trial approval...
Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech
GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has...
China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...
AstraZeneca’s Imfinzi Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer Trial
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has this week announced 3-year...
Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment
Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of...
China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval...
Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor
Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...
Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers
Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a...
Roche’s Columvi Meets Overall Survival Endpoint in Diffuse Large B-Cell Lymphoma Trial
Roche (SWX: RO), a leading Swiss pharmaceutical company, has announced that a late-stage clinical trial...
Novartis’s Fabhalta Shows Promise in Phase III IgA Nephropathy Trial
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive preliminary results from a Phase III...
Keymed Biosciences Achieves First Dosing in Global Phase III Trial for Claudin 18.2 Targeting ADC
Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced the completion...
Hengrui Pharmaceuticals Gets NMPA Approval for Clinical Study of CDK 4/6 Inhibitor Combo in Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...
3SBio Secures NMPA Approval for Pediatric Thrombopoietin Treatment of ITP
3SBio Inc. (HKG: 1530), a leading biopharmaceutical company based in China, has announced that it...